Combination therapy for treatment of infections with gram-negative bacteria

Clinical Microbiology Reviews

Volumn 25, Issue 3, 2012, Pages 450-470

  Tamma, Pranita D ^a   Cosgrove, Sara E ^a   Maragakis, Lisa L ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AZLOCILLIN; AZTREONAM; BETA LACTAM; CARBAPENEM; CARBENICILLIN; CEFTAZIDIME; CIPROFLOXACIN; CLAVULANATE POTASSIUM PLUS TICARCILLIN; CLINDAMYCIN; COLISTIN; GENTAMICIN; IMIPENEM; NETILMICIN; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; TOBRAMYCIN;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTIFICIAL VENTILATION; BACTERIAL INFECTION; BURKHOLDERIA CEPACIA INFECTION; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE SEVERITY; ENDOCARDITIS; EVIDENCE BASED PRACTICE; FEVER; GRAM NEGATIVE BACTERIUM; HEART ARREST; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; LOW DRUG DOSE; LOWER RESPIRATORY TRACT INFECTION; MENTAL HEALTH; MONOTHERAPY; MORTALITY; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OTOTOXICITY; PSEUDOMONAS INFECTION; REVIEW; SEPSIS; SEPTIC SHOCK; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; NEUTROPENIA; TREATMENT OUTCOME;

NEGIBACTERIA;

EID: 84863654489     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.05041-11     Document Type: Review

References (255)

1. Aaron SD, Ferris W, Henry DA, Speert DP, Macdonald NE. 2000. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am. J. Respir. Crit. Care Med. 161:1206-1212.
2. Aaron SD, et al. 2002. Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis. J. Clin. Microbiol. 40:4172-4179.
3. Aaron SD, et al. 2005. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 366: 463-471.
4. Aarts MA, Hancock JN, Heyland D, McLeod RS, Marshall JC. 2008. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit. Care Med. 36:108-117.
5. Al-Hasan MN, et al. 2009. Beta-lactam and fluoroquinolone combination antibiotic therapy for bacteremia caused by gram-negative bacilli. Antimicrob. Agents Chemother. 53:1386-1394.
6. Alvarez-Lerma F. 1996. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICUAcquired Pneumonia Study Group. Intensive Care Med. 22:387-394.
7. Alvarez Lerma F. 2001. Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia. J. Chemother. 13:70-81.
8. American Thoracic Society. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcareassociated pneumonia. Am. J. Respir. Crit. Care Med. 171:388-416.
9. Anderson ET, Young LS, Hewitt WL. 1978. Antimicrobial synergism in the therapy of gram-negative rod bacteremia. Chemotherapy 24:45-54.
10. Andriole VT. 1974. Antibiotic synergy in experimental infection with Pseudomonas. II. The effect of carbenicillin, cephalothin, or cephanone combined with tobramycin or gentamicin. J. Infect. Dis. 129:124-133.
11. Andriole VT. 1971. Synergy of carbenicillin and gentamicin in experimental infection with Pseudomonas. J. Infect. Dis. 124(Suppl.):S46-S55.
12. Angeras MH, et al. 1996. A comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intraabdominal infections. Scand. J. Infect. Dis. 28:513-518.
13. Aoun M, Klastersky J. 1991. Drug treatment of pneumonia in the hospital. What are the choices? Drugs 42:962-973.
14. Archer G, Fekety FR, Jr. 1977. Experimental endocarditis due to Pseudomonas aeruginosa. II. Therapy with carbenicillin and gentamicin. J. Infect. Dis. 136:327-335.
15. Badaro R, et al. 2002. A multicenter comparative study of cefepime versus broad-spectrum antibacterial therapy in moderate and severe bacterial infections. Braz J. Infect. Dis. 6:206-218.
16. Barie PS, Hydo LJ, Shou J, Eachempati SR. 2006. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis. Surg. Infect. (Larchmt.) 7(Suppl. 2):S77-S80.
17. Barie PS, et al. 1997. A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-Abdominal Infection Study Group. Arch. Surg. 132:1294-1302.
18. Beardsley JR, et al. 2006. Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest 130:787-793.
19. Beaubien AR, et al. 1991. Evidence that amikacin ototoxicity is related to total perilymph area under the concentration-time curve regardless of concentration. Antimicrob. Agents Chemother. 35:1070-1074.
20. Bhat S, et al. 2007. Pseudomonas aeruginosa infections in the intensive care unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved? Int. J. Antimicrob. Agents 30:458-462.
21. Bisbe J, et al. 1988. Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing the prognosis in 133 episodes. Rev. Infect. Dis. 10:629-635.
22. Bliziotis IA, et al. 2005. Ciprofloxacin vs an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials. Mayo Clin. Proc. 80: 1146-1156.
23. Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME. 2005. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin. Infect. Dis. 41:149-158.
24. Bodey GP, Elting LS, Rodriguez S. 1991. Bacteremia caused by Enterobacter: 15 years of experience in a cancer hospital. Rev. Infect. Dis. 13: 550-558.
25. Bodey GP, Jadeja L, Elting L. 1985. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch. Intern. Med. 145:1621-1629.
26. Bodey GP, Middleman E, Umsawadi T, Rodriguez V. 1972. Infections in cancer patients. Results with gentamicin sulfate therapy. Cancer 29: 1697-1701.
27. Bonomo RA, Szabo D. 2006. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin. Infect. Dis. 43(Suppl. 2):S49-S56.
28. Bouza E, Munoz P. 2000. Monotherapy versus combination therapy for bacterial infections. Med. Clin. North Am. 84:1357-1389, 5.
29. Bradley JS, Jackson MA. 2011. The use of systemic and topical fluoroquinolones. Pediatrics 128:e1034-e1045.
30. Bratu S, et al. 2005. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch. Intern. Med. 165:1430-1435.
31. Bratu S, et al. 2005. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J. Antimicrob. Chemother. 56:128-132.
32. Brummett RE, Fox KE. 1989. Aminoglycoside-induced hearing loss in humans. Antimicrob. Agents Chemother. 33:797-800.
33. Bryan CS, Reynolds KL, Brenner ER. 1983. Analysis of 1,186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy. Rev. Infect. Dis. 5:629-638.
34. Burgess DS, Nathisuwan S. 2002. Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa. Diagn. Microbiol. Infect. Dis. 44:35-41.
35. Bush K. 2010. Alarming beta-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Curr. Opin. Microbiol. 13:558-564.
36. Bush K. 2010. Bench-to-bedside review: the role of beta-lactamases in antibiotic-resistant Gram-negative infections. Crit. Care 14:224.
37. Bustamante CI, Wharton RC, Wade JC. 1990. In vitro activity of ciprofloxacin in combination with ceftazidime, aztreonam, and azlocillin against multiresistant isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 34:1814-1815.
38. Calandra T, Glauser MP. 1986. Immunocompromised animal models for the study of antibiotic combinations. Am. J. Med. 80:45-52.
39. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. 1999. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob. Agents Chemother. 43:1379-1382.
40. Carmeli Y, Troillet N, Karchmer AW, Samore MH. 1999. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch. Intern. Med. 159:1127-1132.
41. Carroll JD, et al. 1989. A new methicillin- and gentamicin-resistant Staphylococcus aureus in Dublin: molecular genetic analysis. J. Med. Microbiol. 28:15-23.
42. Celis R, et al. 1988. Nosocomial pneumonia. A multivariate analysis of risk and prognosis. Chest 93:318-324.
43. Chaisson RE. 2003. Treatment of chronic infections with rifamycins: is resistance likely to follow? Antimicrob. Agents Chemother. 47:3037-3039.
44. Chamot E, Boffi El-Amari E, Rohner P, van Delden C. 2003. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob. Agents Chemother. 47:2756-2764.
45. Chandrasekar PH, Crane LR, Bailey EJ. 1987. Comparison of the activity of antibiotic combinations in vitro with clinical outcome and resistance emergence in serious infection by Pseudomonas aeruginosa in non-neutropenic patients. J. Antimicrob. Chemother. 19:321-329.
46. Chang YC, Huang CC, Wang ST, Chio CC. 1997. Risk factor of complications requiring neurosurgical intervention in infants with bacterial meningitis. Pediatr. Neurol. 17:144-149.
47. Chen YH, et al. 2011. Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intraabdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria. J. Infect. 62:280-291.
48. Chow JW, et al. 1991. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann. Intern. Med. 115:585-590.
49. Cohn SM, et al. 2000. Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann. Surg. 232:254-262.
50. Comber KR, Basker MJ, Osborne CD, Sutherland R. 1977. Synergy between ticarcillin and tobramycin against Pseudomonas aeruginosa and Enterobacteriaceae in vitro and in vivo. Antimicrob. Agents Chemother. 11:956-964.
51. Cometta A, et al. 1994. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob. Agents Chemother. 38:1309-1313.
52. Conway SP, et al. 1997. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 52:987-993.
53. Cosgrove SE, et al. 2009. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin. Infect. Dis. 48: 713-721.
54. Crabtree TD, Pelletier SJ, Gleason TG, Pruett TL, Sawyer RG. 1999. Analysis of aminoglycosides in the treatment of gram-negative infections in surgical patients. Arch. Surg. 134:1293-1299.
55. Croce MA, et al. 1993. Empiric monotherapy versus combination therapy of nosocomial pneumonia in trauma patients. J. Trauma. 35:303-309 discussion 309-311.
56. Daikos GL, et al. 2009. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob. Agents Chemother. 53:1868-1873.
57. Darras-Joly C, et al. 1996. Synergy between amoxicillin and gentamicin in combination against a highly penicillin-resistant and-tolerant strain of Streptococcus pneumoniae in a mouse pneumonia model. Antimicrob. Agents Chemother. 40:2147-2151.
58. de Jongh CA, et al. 1986. Antibiotic synergism and response in gramnegative bacteremia in granulocytopenic cancer patients. Am. J. Med. 80:96-100.
59. de Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP. 1994. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group. Ann. Intern. Med. 120:834-844.
60. Deaney NB, Tate H. 1996. A meta-analysis of clinical studies of imipenem-cilastatin for empirically treating febrile neutropenic patients. J. Antimicrob. Chemother. 37:975-986.
61. den Hollander JG, Horrevorts AM, van Goor ML, Verbrugh HA, Mouton JW. 1997. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 41:95-100.
62. Drenkard E, Ausubel FM. 2002. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 416:740-743.
63. Drusano GL, Liu W, Fregeau C, Kulawy R, Louie A. 2009. Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant. Antimicrob. Agents Chemother. 53:2266-2273.
64. Dulon D, Aran JM, Zajic G, Schacht J. 1986. Comparative uptake of gentamicin, netilmicin, and amikacin in the guinea pig cochlea and vestibule. Antimicrob. Agents Chemother. 30:96-100.
65. Dupont H, Carbon C, Carlet J. 2000. Monotherapy with a broadspectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. The Severe Generalized Peritonitis Study Group. Antimicrob. Agents Chemother. 44:2028-2033.
66. El-Amari EB, Chamot E, Auckenthaler R, Pechere JC, van Delden C. 2001. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin. Infect. Dis. 33:1859-1864.
67. Eliopoulos GM, Eliopoulos CT. 1988. Antibiotic combinations: should they be tested? Clin. Microbiol. Rev. 1:139-156.
68. Elphick HE, Tan A. 2005. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane Database Syst. Rev. 2005:CD002007. doi:10.1002/14651858.CD002007.pub2.
69. Elphick HE, Tan A. 2001. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane Database Syst. Rev. 2001:CD002007. doi:10.1056/NEJM198712313172703.
70. EORTC International Antimicrobial Therapy Cooperative Group. 1987. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N. Engl. J. Med. 317:1692-1698.
71. Fainstein V, et al. 1983. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients. J. Antimicrob. Chemother. 12(Suppl. A):101-110.
72. Falagas ME, Barefoot L, Griffith J, Ruthazar R, Snydman DR. 1996. Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections. Eur. J. Clin. Microbiol. Infect. Dis. 15:913-921.
73. Falagas ME, Karageorgopoulos DE, Nordmann P. 2011. Therapeutic options for infections with Enterobacteriaceae producing carbapenemhydrolyzing enzymes. Future Microbiol. 6:653-666.
74. Falagas ME, et al. 2010. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int. J. Antimicrob. Agents 35:194-199.
75. Falagas ME, Rafailidis PI, Kasiakou SK, Hatzopoulou P, Michalopoulos A. 2006. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin. Microbiol. Infect. 12:1227-1230.
76. Farthmann EH, Schoffel U. 1990. Principles and limitations of operative management of intraabdominal infections. World J. Surg. 14:210-217.
77. Fink MP. 1991. Antibiotic therapy of intra-abdominal sepsis in the elderly: experience with ticarcillin and clavulanic acid. Surg. Gynecol. Obstet. 172(Suppl.):36-41.
78. Fish DN, Choi MK, Jung R. 2002. Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. J. Antimicrob. Chemother. 50:1045-1049.
79. Fish DN, Piscitelli SC, Danziger LH. 1995. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 15:279-291.
80. Freifeld AG, et al. 2011. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 52:427-431.
81. Furno P, Bucaneve G, del Favero A. 2002. Monotherapy or aminoglycoside- containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect. Dis. 2:231-242.
82. Gadaleta P, Kaufman S, Martini P, Zorzopulos J. 1991. A staphylococcal plasmid that replicates and expresses ampicillin, gentamicin and amikacin resistance in Escherichia coli. FEMS Microbiol. Lett. 64:147-150.
83. Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. 2001. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32(Suppl. 2):S146-S155.
84. Garcia-Sabrido JL, Tallado JM, Christou NV, Polo JR, Valdecantos E. 1988. Treatment of severe intra-abdominal sepsis and/or necrotic foci by an 'open-abdomen' approach. Zipper and zipper-mesh techniques. Arch. Surg. 123:152-156.
85. Garnacho-Montero J, et al. 2003. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit. Care Med. 31:2742-2751.
86. Garnacho-Montero J, et al. 2008. Mortality and morbidity attributable to inadequate empirical antimicrobial therapy in patients admitted to the ICU with sepsis: a matched cohort study. J. Antimicrob. Chemother. 61:436-441.
87. Garnacho-Montero J, et al. 2007. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit. Care Med. 35:1888-1895.
88. Gasink LB, Fishman NO, Nachamkin I, Bilker WB, Lautenbach E. 2007. Risk factors for and impact of infection or colonization with aztreonam-resistant Pseudomonas aeruginosa. Infect. Control Hosp. Epidemiol. 28:1175-1180.
89. Gasink LB, et al. 2006. Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am. J. Med. 119:526 e519-e525.
90. Geerdes HF, et al. 1992. Septicemia in 980 patients at a university hospital in Berlin: prospective studies during 4 selected years between 1979 and 1989. Clin. Infect. Dis. 15:991-1002.
91. Gerber AU, Vastola AP, Brandel J, Craig WA. 1982. Selection of aminoglycoside-resistant variants of Pseudomonas aeruginosa in an in vivo model. J. Infect. Dis. 146:691- 697.
92. Giamarellou H. 1986. Aminoglycosides plus beta-lactams against gramnegative organisms. Evaluation of in vitro synergy and chemical interactions. Am. J. Med. 80:126-137.
93. Giamarellou H. 2010. Multidrug-resistant Gram-negative bacteria: how to treat and for how long. Int. J. Antimicrob. Agents 36(Suppl. 2):S50-S54.
94. Giamarellou H, et al. 2000. Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrob. Agents Chemother. 44:3264-3271.
95. Giamarellou H, Petrikkos G. 1987. Ciprofloxacin interactions with imipenem and amikacin against multiresistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 31:959-961.
96. Giamarellou H, Zissis NP, Tagari G, Bouzos J. 1984. In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 25:534-536.
97. Gimeno C, et al. 1998. In vitro interaction between ofloxacin and cefotaxime against gram-positive and gram-negative bacteria involved in serious infections. Chemotherapy 44:94-98.
98. Giske CG, Monnet DL, Cars O, Carmeli Y. 2008. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob. Agents Chemother. 52:813-821.
99. Glew RH, Pavuk RA. 1983. Early synergistic interaction between semisynthetic penicillins and aminoglycosidic aminocyclitols against Enterobacteriaceae. Antimicrob. Agents Chemother. 23:902-906.
100. Gradelski E, et al. 2001. Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents. Int. J. Antimicrob. Agents 17:103-107.
101. Grasela TH, Jr, et al. 1990. A nationwide survey of antibiotic prescribing patterns and clinical outcomes in patients with bacterial pneumonia. DICP 24:1220-1225.
102. Gribble MJ, et al. 1983. Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections. Antimicrob. Agents Chemother. 24:388-393.
103. Gudiol C, et al. 2011. Bacteraemia due to multidrug-resistant Gramnegative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J. Antimicrob. Chemother. 66:657-663.
104. Guner R, Hasanoglu I, Keske S, Kalem AK, Tasyaran MA. 2011. Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy. Infection 39:515-518.
105. Hancock RE. 1998. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin. Infect. Dis. 27(Suppl. 1):S93-S99.
106. Hancock RE, Raffle VJ, Nicas TI. 1981. Involvement of the outer membrane in gentamicin and streptomycin uptake and killing in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 19:777-785.
107. Harbarth S, et al. 2003. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am. J. Med. 115:529-535.
108. Hawser SP, et al. 2012. Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum betalactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009). Clin. Microbiol. Infect. 18:253-259.
109. Heath CH, Grove DI, Looke DF. 1996. Delay in appropriate therapy of Legionella pneumonia associated with increased mortality. Eur. J. Clin. Microbiol. Infect. Dis. 15:286-290.
110. Heineman HS, Lofton WM. 1978. Unpredictable response of Pseudomonas aeruginosa to synergistic antibiotic combinations in vitro. Antimicrob. Agents Chemother. 13:827-831.
111. Hibbard ML, et al. 2010. Empiric, broad-spectrum antibiotic therapy with an aggressive de-escalation strategy does not induce gram-negative pathogen resistance in ventilator-associated pneumonia. Surg. Infect. (Larchmt.) 11:427-432.
112. Hidalgo M, et al. 1999. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer 85:213-219.
113. Hilf M, et al. 1989. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am. J. Med. 87:540-546.
114. Hoban DJ, et al. 2010. Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob. Agents Chemother. 54: 3031-3034.
115. Hoepelman IM, Rozenberg-Arska M, Verhoef J. 1988. Comparison of once daily ceftriaxone with gentamicin plus cefuroxime for treatment of serious bacterial infections. Lancet i:1305-1309.
116. Huizinga WK, et al. 1988. Management of severe intra-abdominal sepsis: single agent antibiotic therapy with cefotetan versus combination therapy with ampicillin, gentamicin and metronidazole. Br. J. Surg. 75: 1134-1138.
117. Hyle EP, et al. 2005. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamaseproducing Enterobacteriaceae: variability by site of infection. Arch. Intern. Med. 165:1375-1380.
118. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. 2000. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118:146-155.
119. Ibrahim EH, et al. 2001. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit. Care Med. 29:1109-1115.
120. Jenkins SG, Lewis JW. 1995. Synergistic interaction between ofloxacin and cefotaxime against common clinical pathogens. Infection 23: 154-161.
121. Johnson DE, Thompson B. 1986. Efficacy of single-agent therapy with azlocillin, ticarcillin, and amikacin and beta-lactam/amikacin combinations for treatment of Pseudomonas aeruginosa bacteremia in granulocytopenic rats. Am. J. Med. 80:53-58.
122. Johnson PR, Liu Yin JA, Tooth JA. 1992. A randomized trial of highdose iprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients. J. Antimicrob. Chemother. 30:203-214.
123. Johnston SC. 2001. Identifying confounding by indication through blinded prospective review. Am. J. Epidemiol. 154:276-284.
124. Kang CI, et al. 2003. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin. Infect. Dis. 37:745-751.
125. Kang CI, et al. 2005. Bloodstream infections caused by antibioticresistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob. Agents Chemother. 49:760-766.
126. Kett DH, et al. 2011. Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infect. Dis. 11:181-189.
127. Klastersky J. 1980. Prediction and significance of synergy between antibiotics used for treatment for gram-negative sepsis. Infect. Suppl. 1:45-48.
128. Klastersky J, Cappel R, Daneau D. 1972. Clinical significance of in vitro synergism between antibiotics in gram-negative infections. Antimicrob. Agents Chemother. 2:470-475.
129. Klastersky J, Glauser MP, Schimpff SC, Zinner SH, Gaya H. 1986. Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrob. Agents Chemother. 29:263-270.
130. Klastersky J, Meunier-Carpentier F, Prevost JM. 1977. Significance of antimicrobial synergism for the outcome of gram negative sepsis. Am. J. Med. Sci. 273:157-167.
131. Klastersky J, Zinner SH. 1982. Synergistic combinations of antibiotics in gram-negative bacillary infections. Rev. Infect. Dis. 4:294-301.
132. Klibanov OM, Raasch RH, Rublein JC. 2004. Single versus combined antibiotic therapy for gram-negative infections. Ann. Pharmacother. 38: 332-337.
133. Kluge RM, et al. 1974. Comparative activity of tobramycin, amikacin, and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 6:442-446.
134. Kollef M. 2003. Appropriate empirical antibacterial therapy for nosocomial infections: getting it right the first time. Drugs 63:2157-2168.
135. Kollef MH. 2000. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin. Infect. Dis. 31(Suppl. 4):S131-S138.
136. Kollef MH, Fraser VJ. 2001. Antibiotic resistance in the intensive care unit. Ann. Intern. Med. 134:298-314.
137. Kollef MH, Sherman G, Ward S, Fraser VJ. 1999. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462-474.
138. Kollef MH, Ward S. 1998. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 113:412-420.
139. Korvick JA, et al. 1992. Prospective observational study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy. Antimicrob. Agents Chemother. 36:2639-2644.
140. Kosmidis J, Koratzanis G. 1986. Emergence of resistant bacterial strains during treatment of infections in the respiratory tract. Scand. J. Infect. Dis. Suppl. 49:135-139.
141. Kreger BE, Craven DE, McCabe WR. 1980. Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am. J. Med. 68:344-355.
142. Kumar A, et al. 2009. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 136:1237-1248.
143. Kumar A, Safdar N, Kethireddy S, Chateau D. 2010. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a metaanalytic/meta-regression study. Crit. Care Med. 38:1651-1664.
144. Kumar A, Wofford-McQueen R, Gordon RC. 1989. Ciprofloxacin, imipenem and rifampicin: in-vitro synergy of two and three drug combinations against Pseudomonas cepacia. J. Antimicrob. Chemother. 23: 831-835.
145. Kumar A, et al. 2010. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit. Care Med. 38:1773-1785.
146. Kwon KT, et al. 2007. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J. Antimicrob. Chemother. 59: 525-530.
147. Lautenbach E, Metlay JP, Bilker WB, Edelstein PH, Fishman NO. 2005. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin. Infect. Dis. 41:923-929.
148. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. 2001. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin. Infect. Dis. 32:1162-1171.
149. Lautenbach E, et al. 2010. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect. Control Hosp. Epidemiol. 31:47-53.
150. Lautenbach E, et al. 2006. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect. Control Hosp. Epidemiol. 27: 893-900.
151. Lee J, Patel G, Huprikar S, Calfee DP, Jenkins SG. 2009. Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection. J. Clin. Microbiol. 47:1611-1612.
152. Lee SO, et al. 2002. Impact of previous use of antibiotics on development f resistance to extended-spectrum cephalosporins in patients with enterobacter bacteremia. Eur. J. Clin. Microbiol. Infect. Dis. 21:577-581.
153. Leibovici L, et al. 1997. Monotherapy versus beta-lactamaminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob. Agents Chemother. 41: 1127-1133.
154. Leibovici L, et al. 1995. Long-term survival following bacteremia or fungemia. JAMA 274:807-812.
155. Linden PK, et al. 2003. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin. Infect. Dis. 37:e154-e160.
156. Lister PD, Wolter DJ. 2005. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa. Clin. Infect. Dis. 40(Suppl. 2):S105-S114.
157. Lister PD, Wolter DJ, Wickman PA, Reisbig MD. 2006. Levofloxacin/imipenem prevents the emergence of high-level resistance among Pseudomonas aeruginosa strains already lacking susceptibility to one or both drugs. J. Antimicrob. Chemother. 57:999-1003.
158. Livermore DM. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34: 634-640.
159. Luna CM, et al. 1997. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 111:676-685.
160. Malik IA, Abbas Z, Karim M. 1992. Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet 339:1092-1096.
161. Maragakis LL. 2010. Recognition and prevention of multidrug-resistant Gram-negative bacteria in the intensive care unit. Crit. Care Med. 38: S345-S351.
162. Marcus R, Paul M, Elphick H, Leibovici L. 2011. Clinical implications of beta-lactam-aminoglycoside synergism: systematic review of randomized trials. Int. J. Antimicrob. Agents 37:491-503.
163. Martinez JA, et al. 2010. Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. Antimicrob. Agents Chemother. 54:3590-3596.
164. McDonald LC, Owings M, Jernigan DB. 2006. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg. Infect. Dis. 12:409-415.
165. Mehtar S, Dewar EP, Leaper DJ, Taylor EW. 1997. A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections. J. Antimicrob. Chemother. 39:631-638.
166. Micek ST, et al. 2005. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob. Agents Chemother. 49:1306-1311.
167. Micek ST, et al. 2010. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrob. Agents Chemother. 54:1742-1748.
168. Milatovic D, Braveny I. 1987. Development of resistance during antibiotic therapy. Eur. J. Clin. Microbiol. 6:234-244.
169. Milatovic D, Wallrauch C. 1996. In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin. Eur. J. Clin. Microbiol. Infect. Dis. 15:688-693.
170. Miller MH, Feinstein SA, Chow RT. 1987. Early effects of beta-lactams on aminoglycoside uptake, bactericidal rates, and turbidimetrically measured growth inhibition in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 31:108-110.
171. Moellering RC, Jr, Weinberg AN. 1971. Studies on antibiotic syngerism against enterococci. II. Effect of various antibiotics on the uptake of 14 C-labeled streptomycin by enterococci. J. Clin. Invest. 50:2580-2584.
172. Moellering RC, Jr, Wennersten C, Weinberg AN. 1971. Studies on antibiotic synergism against enterococci. I. Bacteriologic studies. J. Lab. Clin. Med. 77:821-828.
173. Montravers P, et al. 1996. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin. Infect. Dis. 23:486-494.
174. Montravers P, et al. 2002. Diagnostic and therapeutic management of nosocomial pneumonia in surgical patients: results of the Eole study. Crit. Care Med. 30:368-375.
175. Moore RD, Lerner SA, Levine DP. 1992. Nephrotoxicity and ototoxicity of aztreonam versus aminoglycoside therapy in seriously ill nonneutropenic patients. J. Infect. Dis. 165:683-688.
176. Mosdell DM, et al. 1991. Antibiotic treatment for surgical peritonitis. Ann. Surg. 214:543-549.
177. Moskowitz SM, Foster JM, Emerson J, Burns JL. 2004. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J. Clin. Microbiol. 42:1915-1922.
178. Mouloudi E, et al. 2010. Bloodstream infections caused by metallo-betalactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infect. Control Hosp. Epidemiol. 31:1250-1256.
179. Mouton JW. 1999. Combination therapy as a tool to prevent emergence of bacterial resistance. Infection 27(Suppl. 2):S24-S28.
180. Mouton RP, et al. 1990. Correlations between consumption of antibiotics and methicillin resistance in coagulase negative staphylococci. J. Antimicrob. Chemother. 26:573-583.
181. Mouton YJ, Beuscart C. 1995. Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group. J. Antimicrob. Chemother. 36(Suppl. A):145-156.
182. Nagai J, Tanaka H, Nakanishi N, Murakami T, Takano M. 2001. Role of megalin in renal handling of aminoglycosides. Am. J. Physiol. Renal Physiol. 281:F337-F344.
183. National Nosocomial Infections Surveillance System. 1999. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am. J. Infect. Control 27:520-532.
184. Neu HC. 1993. Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents. Drugs 45(Suppl. 3):54-58.
185. Neuhauser MM, et al. 2003. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289:885-888.
186. Nichols L, Maki DG. 1985. The emergence of resistance to beta-lactam antibiotics during treatment of Pseudomonas aeruginosa lower respiratory tract infections: is combination therapy the solution? Chemioterapia 4:102-109.
187. Niederman MS. 2006. Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms. Clin. Infect. Dis. 42(Suppl. 2):S72-S81.
188. Obritsch MD, Fish DN, MacLaren R, Jung R. 2004. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob. Agents Chemother. 48:4606-4610.
189. Ohlin B, Cederberg A, Forssell H, Solhaug JH, Tveit E. 1999. Piperacillin/tazobactam compared with cefuroxime/ metronidazole in the treatment of intra-abdominal infections. Eur. J. Surg. 165:875-884.
190. Pankuch GA, Lin G, Seifert H, Appelbaum PC. 2008. Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Antimicrob. Agents Chemother. 52:333-336.
191. Paramythiotou E, et al. 2004. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin. Infect. Dis. 38:670-677.
192. Paterson DL. 2008. Impact of antibiotic resistance in gram-negative bacilli on empirical and definitive antibiotic therapy. Clin. Infect. Dis. 47(Suppl. 1):S14-S20.
193. Paterson DL, Bonomo RA. 2005. Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev. 18:657-686.
194. Paterson DL, Doi Y. 2007. A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin. Infect. Dis. 45:1179-1181.
195. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. 2004. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 328:668.
196. Paul M, Leibovici L. 2005. Combination antibiotic therapy for Pseudomonas aeruginosa bacteraemia. Lancet Infect. Dis 5:192-194.
197. Paul M, Leibovici L. 2009. Combination antimicrobial treatment versus monotherapy: the contribution of meta-analyses. Infect. Dis. Clin. North Am. 23:277-293.
198. Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L. 2006. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst. Rev. 2006:CD003344. doi:10.1002/14651858.CD003344.pub2.
199. Paul M, Soares-Weiser K, Grozinsky S, Leibovici L. 2002. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst. Rev. 2002:CD003038. doi:10.1002/14651858.CD003038.
200. Paul M, Soares-Weiser K, Grozinsky S, Leibovici L. 2003. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst. Rev. 2003:CD003038. doi:10.1136/bmj.326.7399.1111.
201. Paul M, Soares-Weiser K, Leibovici L. 2003. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 326:1111.
202. Pechere JC, Marchou B, Michea-Hamzehpour M, Auckenthaler R. 1986. Emergence of resistance after therapy with antibiotics used alone or combined in a murine model. J. Antimicrob. Chemother. 17(Suppl. A): 11-18.
203. Pepin J, et al. 2005. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin. Infect. Dis. 41:1254-1260.
204. Perez F, et al. 2007. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51:3471-3484.
205. Perl TM, Dvorak L, Hwang T, Wenzel RP. 1995. Long-term survival and function after suspected gram-negative sepsis. JAMA 274:338-345.
206. Poenaru D, de Santis M, Christou NV. 1990. Imipenem versus tobramycin-antianaerobe antibiotic therapy in intra-abdominal infections. Can. J. Surg. 33:415-422.
207. Pohlman JK, Knapp CC, Ludwig MD, Washington JA. 1996. Timed killing kinetic studies of the interaction between ciprofloxacin and betalactams against gram-negative bacilli. Diagn. Microbiol. Infect. Dis. 26: 29-33.
208. Reinhardt A, et al. 2007. Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. Antimicrob. Agents Chemother. 51:1341-1350.
209. Rello J, Gallego M, Mariscal D, Sonora R, Valles J. 1997. The value of routine microbial investigation in ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 156:196-200.
210. Rice LB. 2009. The clinical consequences of antimicrobial resistance. Curr. Opin. Microbiol. 12:476-481.
211. Rice LB. 2008. For the duration-rational antibiotic administration in an era of antimicrobial resistance and clostridium difficile. Clin. Infect. Dis. 46:491-496.
212. Romero-Vivas J, Rubio M, Fernandez C, Picazo JJ. 1995. Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 21:1417-1423.
213. Rubinstein E, Lode H, Grassi C. 1995. Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired gram-negative infections. Antibiotic Study Group. Clin. Infect. Dis. 20:1217-1228.
214. Safdar N, Handelsman J, Maki DG. 2004. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A metaanalysis. Lancet Infect. Dis. 4:519-527.
215. Saiman L, Chen Y, Gabriel PS, Knirsch C. 2002. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob. Agents Chemother. 46:1105-1107.
216. Saiman L, et al. 1996. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin. Infect. Dis. 23:532-537.
217. San Gabriel P, et al. 2004. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 48:168-171.
218. Sande MA, Courtney KB. 1976. Nafcillin-gentamicin synergism in experimental staphylococcal endocarditis. J. Lab. Clin. Med. 88:118-124.
219. Sande MA, Irvin RG. 1974. Penicillin-aminoglycoside synergy in experimental Streptococcus viridans endocarditis. J. Infect. Dis. 129:572-576.
220. Sanders CC, Sanders WE, Jr. 1985. Microbial resistance to newer generation beta-lactam antibiotics: clinical and laboratory implications. J. Infect. Dis. 151:399-406.
221. Sanders JW, Powe NR, Moore RD. 1991. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis. J. Infect. Dis. 164:907-916.
222. Sanders WE, Jr., Sanders CC. 1988. Inducible beta-lactamases: clinical and epidemiologic implications for use of newer cephalosporins. Rev. Infect. Dis. 10:830-838.
223. Sandora TJ, et al. 2011. Epidemiology and risk factors for Clostridium difficile infection in children. Pediatr. Infect. Dis. J. 30:580-584.
224. Schentag JJ, Jusko WJ. 1977. Gentamicin persistence in the body. Lancet 1:486.
225. Schentag JJ, et al. 1983. A randomized clinical trial of moxalactam alone versus tobramycin plus clindamycin in abdominal sepsis. Ann. Surg. 198:35-41.
226. Schimpff S, Satterlee W, Young VM, Serpick A. 1971. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N. Engl. J. Med. 284:1061-1065.
227. Schwaber MJ, Carmeli Y. 2007. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J. Antimicrob. Chemother. 60:913-920.
228. Servais H, Jossin Y, Van Bambeke F, Tulkens PM, Mingeot-Leclercq MP. 2006. Gentamicin causes apoptosis at low concentrations in renal LLC-PK1 cells subjected to electroporation. Antimicrob. Agents Chemother. 50:1213-1221.
229. Sieger B, Berman SJ, Geckler RW, Farkas SA. 1997. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group. Crit. Care Med. 25:1663-1670.
230. Siegman-Igra Y, Ravona R, Primerman H, Giladi M. 1998. Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. Int. J. Infect. Dis. 2:211-215.
231. Singh PK, et al. 2000. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407:762-764.
232. Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. 2003. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 123:1495-1502.
233. Solomkin J, Zhao YP, Ma EL, Chen MJ, Hampel B. 2009. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections. Int. J. Antimicrob. Agents 34:439-445.
234. Solomkin JS, Dellinger EP, Christou NV, Busuttil RW. 1990. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. Ann. Surg. 212:581-591.
235. Solomkin JS, et al. 2010. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin. Infect. Dis. 50:133-164.
236. Solomkin JS, et al. 1996. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. Ann. Surg. 223:303-315.
237. Soo Hoo GW, Wen YE, Nguyen TV, Goetz MB. 2005. Impact of clinical guidelines in the management of severe hospital-acquired pneumonia. Chest 128:2778-2787.
238. Spellberg B, Powers JH, Brass EP, Miller LG, and Edwards JE, Jr. 2004. Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis. 38:1279-1286.
239. Takahashi K, Kanno H. 1984. Synergistic activities of combinations of beta-lactams, fosfomycin, and tobramycin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 26:789-791.
240. Tamma PD, Cosgrove SE. 2011. Antimicrobial stewardship. Infect. Dis. Clin. North Am. 25:245-260.
241. Tamma PD, Jenh AM, Milstone AM. 2011. Prolonged beta-lactam infusion for Gram-negative infections. Pediatr. Infect. Dis. J. 30:336-337.
242. th Annu. Mett. Infect. Dis. Soc. Am., Boston, MA.
243. Tamma PD, Lee CK. 2009. Use of colistin in children. Pediatr. Infect. Dis. J. 28:534-535.
244. Tamma PD, Putcha N, Suh YD, Van Arendonk KJ, Rinke ML. 2011. Does prolonged beta-lactam infusions improve clinical outcomes compared to intermittent infusions?Ameta-analysis and systematic review of randomized, controlled trials. BMC Infect. Dis. 11:181.
245. Tascini C, et al. 2006. Clinical and microbiological efficacy of colistin therapy alone or in combination as treatment for multidrug resistant Pseudomonas aeruginosa diabetic foot infections with or without osteomyelitis. J. Chemother. 18:648-651.
246. Torres A, et al. 1990. Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am. Rev. Respir. Dis. 142:523-528.
247. van Delden C. 2007. Pseudomonas aeruginosa bloodstream infections: how should we treat them? Int. J. Antimicrob. Agents 30(Suppl. 1):S71-S75.
248. Vidal F, et al. 1996. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch. Intern. Med. 156:2121-2126.
249. Vidal L, et al. 2007. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J. Antimicrob. Chemother. 60:247-257.
250. Vincent JL, et al. 1995. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) study. EPIC International Advisory Committee. JAMA 274:639-644.
251. Wisplinghoff H, et al. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317.
252. Wu YL, Scott EM, Po AL, Tariq VN. 1999. Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa. J. Antimicrob. Chemother. 44:389-392.
253. Yellin AE, et al. 2002. Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults. Int. J. Antimicrob. Agents 20:165-173.
254. Yoshikawa TT, Shibata SA. 1978. In vitro antibacterial activity of amikacin and ticarcillin, alone and in combination, against Pseudomonas aerurginosa. Antimicrob. Agents Chemother. 13:997-999.
255. Zembower TR, Noskin GA, Postelnick MJ, Nguyen C, Peterson LR. 1998. The utility of aminoglycosides in an era of emerging drug resistance. Int. J. Antimicrob. Agents 10:95-105.